{
    "clinical_study": {
        "@rank": "168037", 
        "acronym": "DHA-O", 
        "arm_group": [
            {
                "arm_group_label": "DHA-O", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Fish oil", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of DHA-O to lower\n      elevated triglyceride levels in healthy adults with hypertriglyceridemia."
        }, 
        "brief_title": "Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertriglyceridemia", 
        "condition_browse": {
            "mesh_term": "Hypertriglyceridemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ages 18-79\n\n          -  fasting TG levels, 150-499 mg/dL\n\n          -  baseline DHA intake <200mg/d\n\n          -  active and in good health\n\n        Exclusion Criteria:\n\n          -  recent diagnosis of CHD or history of revascularization within 6mos of study\n\n          -  use of lipid altering medications (other than stable statins)\n\n          -  use of anticoagulants\n\n          -  use of omega-3 products within 4 weeks of screening\n\n          -  serum AST/ALT >1.5x ULN and/or creatinine >1.5 mg/dL at screening\n\n          -  lipid altering foods or supplements\n\n          -  women who are pregnant or of childbearing potential not using adequate birth control\n\n          -  current use or history of  drug or alcohol abuse\n\n          -  inability to swallow capsules"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "93", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737099", 
            "org_study_id": "2012-1048"
        }, 
        "intervention": [
            {
                "arm_group_label": "DHA-O", 
                "intervention_name": "DHA-O", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Fish oil", 
                "intervention_name": "Fish oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "omega-3", 
            "DHA", 
            "triglycerides", 
            "lipids", 
            "cardiovascular", 
            "hypertriglyceridemia"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Addison", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60101"
                }, 
                "name": "Biofortis Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Biofortis Clinical Research", 
            "last_name": "Kevin Maki, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in TG levels", 
            "safety_issue": "No", 
            "time_frame": "week 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737099"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in lipid panel measures", 
            "safety_issue": "No", 
            "time_frame": "week 14"
        }, 
        "source": "DSM Nutritional Products, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DSM Nutritional Products, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}